Key Takeaways
- Strong quarter, guidance on track: Revenue grew 26% YoY to ₹768 crores, with all divisions contributing positively, and management confirmed it is on track to meet its guidance, including the upgraded revenue growth target.
- Zoetis deal is the growth anchor: The long-term biologics agreement, potentially worth up to $500 million over 10 years, passed a key milestone with completed PPQ batches, setting the stage for commercial manufacturing to begin in Q4.
- Margins held despite inflation: EBITDA margin was maintained at similar levels as last year through cost discipline and forward planning with suppliers, even as global inflation rose.
- Profit growth lagged revenue: PAT before exceptional items grew 11% YoY, trailing the 26% revenue growth, weighed down by higher depreciation and an 866.9% jump in finance costs.
- What to watch next quarter: The regulatory audit outcome that will greenlight Zoetis commercial manufacturing, and whether the Discovery Chemistry demand momentum sustains.
Zoetis Partnership & Manufacturing Milestone
- Deal signed, milestone hit: The long-term biologics manufacturing agreement was signed in July 2022, and the process performance qualification (PPQ) batches at commercial scale were successfully completed during Q2.
- Product and potential: The drug substance is for Librela®, a first-of-its-kind injectable monoclonal antibody for pain associated with osteoarthritis in dogs, and the agreement has the potential to be worth up to $500 million over the next 10 years.
- Commercial start line: Commercial manufacturing of the drug substance is likely to begin in Q4 FY23, subject to successful completion of required regulatory audits, which are the next important milestone.
- Transformational claim: The agreement is expected to be transformational for the Manufacturing Services division in the years to come, adding to an existing roster of partnerships with BMS and Amgen.
Hunt: "We are on track for the next important regulatory audits which will pave the way for the commercial manufacturing of the drug substance for Librela®, a Zoetis product, from the fourth quarter of FY23. With a strong first half of the year behind us we are on track to achieve our guidance, including the upgraded revenue growth target announced in July."*
Divisional Performance
- Discovery Services: Sustained demand drove growth, with Discovery Chemistry seeing particularly buoyant customer demand, alongside the integrated drug discovery platform Synvent and the Dedicated Centres.
- Development Services: Growth was led by existing clients renewing contracts and setting up collaborations on additional projects, especially in drug substance development and clinical supplies.
- Manufacturing Services: The quarter's headline event was the completion of PPQ batches at commercial scale for Zoetis, a critical step toward commercial production.
- Underlying H1 strength: Excluding the remdesivir impact in the previous year, H1 performance was strong and reflects a return to normal operations in global markets.
Margins & Cost Structure
- EBITDA margin defended: Despite rising global inflation, cost discipline and forward planning with suppliers prevented supply chain disruption and helped maintain EBITDA margins at similar levels as last year.
- Staff cost efficiency: Staff costs as a percentage of revenue improved to 28.4% in Q2 FY23 from 31.0% in Q2 FY22.
- Material cost leverage: Material costs as a percentage of revenue improved to 25.9% from 27.4% YoY.
- Forex swing: A net forex gain of 18.6 crore was recorded in Q2 FY23, compared to a loss of 10.4 crore in Q2 FY22, a positive swing of 29 crore.
- Below-the-line drags: Finance costs increased 866.9% YoY to 11.7 crore, and depreciation rose to 90.2 crore from 76.2 crore, reflecting ongoing capex and asset additions, both of which weighed on PAT growth.
Biswas: "Forward planning with suppliers prevented supply chain disruption and, despite the rising global inflation, cost discipline helped us maintain EBITDA margins at similar levels as last year."
Market Environment & Investment
- Healthy demand signals: Management is seeing healthy signs of growth in the market for contract research, development and manufacturing services.
- Investment posture: The company continues to invest in infrastructure and capability development to meet the opportunities it sees in the market.
Biswas: "Overall, we are seeing healthy signs of growth in the market for contract research, development and manufacturing services and we continue to invest in infrastructure and capability development to meet these opportunities."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | On track to achieve upgraded revenue growth target announced in July | FY23 |
| Zoetis commercial manufacturing | Begin commercial manufacturing of drug substance for Librela® | Q4 FY23, subject to successful regulatory audits |
| Zoetis agreement value | Potential to be worth up to $500 million | Over the next 10 years |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue from operations | ₹768 crores, up 26% YoY |
| Reported EBITDA | ₹232 crores, up 22% YoY |
| EBITDA margin | 29.6%, vs 30.5% YoY (28.2% from operations margin vs 29.1% YoY) |
| PAT before exceptional item | ₹102 crores, up 11% YoY |
| PAT margin | 13.0%, vs 14.8% YoY |
| PAT after exceptional item | ₹102 crores, up 53% YoY (Q2 FY22: ₹67 crores after SEIS adjustment) |
| H1 FY23 revenue from operations | ₹1,413 crores, up 17% YoY |
| H1 FY23 PAT before exceptional item | ₹176 crores, up 4% YoY |
| Staff costs | 218.5 crore (28.4% of revenue), vs 189.2 crore (31.0%) YoY |
| Finance costs | 11.7 crore, vs 1.2 crore YoY |
| Forex gain | 18.6 crore, vs loss of 10.4 crore YoY |
| Depreciation and amortisation | 90.2 crore, vs 76.2 crore YoY |
| Zoetis agreement potential | Up to $500 million over 10 years |
| Scientists | More than 5,200 |